MDGL FY 2021 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$242M

Net Income

-$242M

EPS (Diluted)

$-14.63

Cash Flow

Operating Cash Flow

-$184M

Free Cash Flow

-$184M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$273M

Total Liabilities

$77M

Stockholders' Equity

$196M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$471,000	+100.0%
Operating Income	-$242M	-$206M	-17.5%
Net Income	-$242M	-$202M	-19.6%